The beating that gene editing stocks took this week on immunogenicity concerns about Cas9, the technology’s workhorse enzyme, are the latest consequence of the field pushing to run while still learning to walk. The field’s scientists, by contrast, see it as one of many surmountable hurdles they are likely to face.
Last Friday, Stanford University professor Matthew Porteus published a study on the preprint server bioRxiv suggesting a large percentage of the human population has pre-existing immunity to the two enzymes most commonly used for CRISPR-based gene editing: Staphylococcus aureus Cas9 and Streptococcus pyogenes Cas9.
On Monday, the three publicly traded CRISPR drug development companies felt the fallout: Intellia Therapeutics Inc. finished down 11.8% from Friday’s close, Editas Medicine Inc. dropped 10.6%, and CRISPR Therapeutics AG fell 2.7%. By today, Intellia and Editas were still down, closing 7.9% and 3.7% off from last Friday’s close, and CRISPR has recovered.
It was the second time in eight months the stocks took a hit based on a preclinical publication -- a rare if not unheard-of event in other areas of drug development. In May, Intellia, Editas and CRISPR Therapeutics fell 0.5-14% after a Nature Medicine paper described a high off-target mutation rate in mice, raising toxicity concerns for the technology. In that case,